Welcome to our dedicated page for Vaxart news (Ticker: VXRT), a resource for investors and traders seeking the latest updates and insights on Vaxart stock.
Vaxart Inc. (VXRT) is a clinical-stage biotechnology company pioneering oral tablet vaccines for infectious diseases. This page aggregates official announcements, financial disclosures, and scientific developments related to its recombinant vaccine platform and clinical pipeline.
Investors and researchers will find timely updates on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection includes earnings reports, manufacturing updates, and peer-reviewed research findings – all essential for evaluating Vaxart's position in the competitive vaccine market.
Key content focuses on tablet vaccine efficacy data, FDA communications, intellectual property developments, and comparative analyses of mucosal immunization approaches. Bookmark this page to monitor Vaxart's progress in redefining vaccine administration through its temperature-stable oral delivery system.
Vaxart (NASDAQ: VXRT) announced that senior scientist Susan Johnson, PhD, will present at ID Week 2021 (Sept 29 - Oct 3) and the 15th Vaccine Congress (Oct 4 - 6). Dr. Johnson's presentation, scheduled for Oct 5, focuses on Vaxart's COVID-19 oral vaccine candidate, highlighting its ability to induce immune responses. The ID Week conference is a collaboration among leading infectious disease organizations, while the Vaccine Congress will gather experts to discuss advancements in vaccine research.
Vaxart, Inc. (NASDAQ: VXRT) announced the formation of a Manufacturing and Quality Advisory Board, aimed at enhancing its vaccine development efforts. The board, convened on August 21, comprises six experts with extensive experience in bioprocess development, regulatory affairs, and quality assurance. CEO Andrei Floroiu expressed excitement about leveraging their insights as Vaxart progresses toward late-stage development and commercialization of its oral vaccine portfolio, which includes candidates for COVID-19 and other viral diseases.
Vaxart, Inc. (NASDAQ: VXRT) announced that CEO Andrei Floroiu and CSO Sean Tucker will present at the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021, at 10:40 a.m. ET. The presentation can be viewed here and on Vaxart's website. Vaxart is advancing its oral tablet COVID-19 vaccine into phase II trials, being the only oral COVID-19 vaccine supported by clinical data. The company develops a variety of oral recombinant vaccines and holds multiple patents for its innovative technology.
Vaxart, Inc. (Nasdaq: VXRT) announced that CEO Andrei Floroiu and CSO Dr. Sean Tucker will present at the H.C. Wainwright 23rd Annual Global Investor Conference from Sept. 13-15, 2021. The presentation will be available on demand starting at 7:00 a.m. ET on Sept. 13. Vaxart's oral tablet COVID-19 vaccine, which has completed phase I trials, is set to enter phase II trials this year, being the only oral vaccine backed by clinical data. Vaxart develops a range of oral vaccines targeting various diseases, supported by its proprietary delivery platform.
Vaxart, Inc. (NASDAQ: VXRT) announced that Dr. Julie M. Cherrington has joined its board of directors. Dr. Cherrington, an accomplished life science executive, brings extensive experience in drug development and commercialization. Her leadership background includes roles as CEO in multiple biotech firms and significant contributions to several FDA-approved products. Vaxart is advancing oral vaccines for COVID-19 and norovirus, positioning itself for transformative impacts in public health. The board expressed optimism regarding Dr. Cherrington's insights as Vaxart progresses in its clinical trials.
Vaxart, Inc. (NASDAQ: VXRT) announced the establishment of a Scientific and Clinical Advisory Board on August 19, 2021. The board includes eight experts in immunology and infectious diseases, with its first meeting held on July 24, 2021. CEO Andrei Floroiu highlighted the board's significance for advancing Vaxart's oral vaccine programs. Members include renowned figures such as Dr. Robert Belshe and Dr. Ralph Baric, who bring extensive experience in vaccine development and research. Vaxart aims to leverage this expertise to enhance public health through its innovative oral vaccine delivery platform.
On August 5, 2021, Vaxart, Inc. (Nasdaq: VXRT) released its second-quarter business update, showcasing progress in oral tablet vaccines. The company raised $36.2 million from its $250 million at-the-market facility and signed a licensing agreement with Altesa Biosciences for its antiviral, Vapendavir, potentially generating $130 million in milestone payments. Financially, Vaxart reported a revenue decrease to $112,000 and a net loss of $16.1 million, compared to $523,000 and $9.0 million in the prior year’s quarter. Research initiatives continue for COVID-19 and norovirus vaccines.
Vaxart, Inc. (NASDAQ: VXRT) announced that the U.S. FDA has cleared its Investigational New Drug application for an S-only oral tablet SARS-CoV-2 vaccine candidate. This milestone allows Vaxart to advance its first S-only vaccine construct, complementing its existing S+N construct, which has completed Phase I trials. Preliminary studies show the S-only vaccine produces higher serum antibodies compared to the S+N vaccine. The Phase II clinical trial for the S-only construct is anticipated to begin in the second half of 2021.
Vaxart, Inc. (Nasdaq: VXRT) announced successful results from a Phase 1b clinical trial showing that its oral norovirus vaccine boosted immune responses in subjects previously vaccinated over a year ago. The study involved 12 participants and demonstrated that both previously vaccinated and unvaccinated individuals showed similar immune responses after receiving a booster dose. Vaxart's CEO emphasized the significance of these findings for developing repeatable oral vaccines for seasonal diseases. The trial results may differentiate Vaxart's vaccines from traditional injectable options.
Vaxart, Inc. (Nasdaq: VXRT) has entered into an exclusive licensing agreement with Altesa Biosciences for Vapendavir, an antiviral targeting enteroviruses. Vaxart can earn up to $130 million in milestone payments and royalties from Vapendavir sales. This licensing deal empowers Altesa to develop and commercialize Vapendavir, which has shown promise in treating infections like human rhinovirus and hand, foot, and mouth disease. Vaxart, focused on oral vaccines, views this collaboration as a way to boost value while addressing global health challenges.
FAQ
What is the current stock price of Vaxart (VXRT)?
What is the market cap of Vaxart (VXRT)?
